BETHESDA, Maryland, October 20, 2016 /PRNewswire/ --
Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company's latest cancer HTS research overtly conclude that, depending upon the THC/CBD ratio, specific Cannabis extracts are directly contributive to reducing U87MG glioblastoma cell viability. The Company expects that results on additional types of cancers will be attained during December 2016.
"The Cannabics' method of diagnosis clearly differentiates between a multitude of varied plant extracts and their apoptotic and necrotic effects by utilizing state of the art HTS (High Through-put Screening) on cells derived from patients' biopsies; the results of which are visualized in "scans" of the before, during and after effect upon the cancer cells themselves" said Dr. Eyal Ballan, Chief Scientist of Cannabics Pharmaceuticals Inc. "When cross linked with patients' medical database and proprietary plant extracts, patients may receive a personalized anticancer therapy combined with the palliative effect of cannabis."
Eyal Barad, co-founder of the Company stated "We are pioneers in the recruitment of HTS technology to evaluate the anti-cancer properties of cannabinoid compounds through the assessment of their observed biological activity on cancer cell lines and patients' tumor cells". "We are also actively developing proprietary and novel compounds specifically targeted on diverse types of tumors. These compounds will be further examined in controlled clinical studies in Israel and finally it is expected through the US FDA." Due to exceptional interest and support from the bio-tech industry, the company has now drawn plans to establish a Cancer HTS lab in a GLP certified high-complexity testing laboratory in Israel beginning in 2017.
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and academic research as well as current clinical studies underway at Rambam Hospital. The Company's scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids. Cannabics' vision is to create individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 13th, 2016. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
SOURCE Cannabics Pharmaceuticals Inc.